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Ghrelin (GHR) is an orexigenic gut peptide that modulates multiple homeostatic functions
including gastric emptying, anxiety, stress, memory, feeding, and reinforcement. GHR is
known to bind and activate growth-hormone secretagogue receptors (termed GHR-Rs).
Of interest to our laboratory has been the assessment of the impact of GHR modulation
of the locomotor activation and reward/reinforcement properties of psychostimulants such
as cocaine and nicotine. Systemic GHR infusions augment cocaine stimulated locomotion
and conditioned place preference (CPP) in rats, as does food restriction (FR) which elevates
plasma ghrelin levels. Ghrelin enhancement of psychostimulant function may occur owing
to a direct action on mesolimbic dopamine function or may reflect an indirect action
of ghrelin on glucocorticoid pathways. Genomic or pharmacological ablation of GHR-Rs
attenuates the acute locomotor-enhancing effects of nicotine, cocaine, amphetamine
and alcohol and blunts the CPP induced by food, alcohol, amphetamine and cocaine
in mice. The stimulant nicotine can induce CPP and like amphetamine and cocaine,
repeated administration of nicotine induces locomotor sensitization in rats. Inactivation
of ghrelin circuit function in rats by injection of a ghrelin receptor antagonist (e.g., JMV
2959) diminishes the development of nicotine-induced locomotor sensitization. These
results suggest a key permissive role for GHR-R activity for the induction of locomotor
sensitization to nicotine. Our finding that GHR-R null rats exhibit diminished patterns of
responding for intracranial self-stimulation complements an emerging literature implicating
central GHR circuits in drug reward/reinforcement. Finally, antagonism of GHR-Rs may
represent a smoking cessation modality that not only blocks nicotine-induced reward but
that also may limit weight gain after smoking cessation.
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INTRODUCTION
The accumulation of excess body fat in obesity is a key eti-
ological factor in current health disorders and early mortality
(Olshansky et al., 2005). In spite of efforts to identify the under-
lying metabolic, hormonal, and behavioral underpinnings of this
disorder, there is evidence that the prevalence of obesity is increas-
ing in American children, adults and the elderly (Fakhouri et al.,
2012; Flegal et al., 2012; Ogden et al., 2012). In recent years,
considerable effort sought to determine effective treatments for
obesity including drugs that either alter metabolism, dimin-
ish nutrient absorption or suppress appetite (Bray, 2000). One
approach has focused on targeting physiological factors that con-
trol eating (Bray, 2000) with the hope that strategies might be
developed to block orexigenic circuits or to facilitate the activity
of circuits that suppress eating. A key example of the latter was the
identification of leptin, a peptide that functions to suppress eat-
ing. Although there was initial enthusiasm that leptin-modulating
drugs might reduce appetite and normalize body weight in obese
subjects (Zhang et al., 1994; Nogueiras et al., 2008), leptin treat-
ments are not effective as antiobesity agents (Hukshorn and
Saris, 2004). With regard to modulation of orexigenic circuits,
a recent candidate peptide has been the gastric peptide ghrelin
(GHR), which is the only peripheral orexigenic peptide identi-
fied to date (Kojima et al., 1999; Tschop et al., 2000; Ariyasu
et al., 2001; Asakawa et al., 2005). Antagonism of ghrelin receptors
presumably would suppress appetite and thus represent a novel
therapeutic approach for obesity (Asakawa et al., 2003).
GHRELIN AND GHRELIN RECEPTORS
In 1999, the Kojima group identified GHR as a 28 amino acid
peptide secreted from the endocrine cells of the stomach and
gut (Kojima et al., 1999). GHR is unique in that this peptide
undergoes a posttranslational modification in which an octanoate
group is added to the third serine group to form acylated-GHR.
(Hosoda et al., 2000; Sakata et al., 2009; Davis et al., 2012). Acyl-
GHR (hereafter referred to as GHR) is the endogenous ligand for
the growth hormone (GH) secretagogue 1a receptor (GHS-R1a
or GHR-R) (Kojima et al., 1999). Unlike GHR, the non-acylated
form of ghrelin (des-acyl-ghrelin or DAG) does not activate GHR-
Rs (Kojima et al., 1999; Delhanty et al., 2012). Normally, circulat-
ing DAG levels are higher than those of GHR levels (Ferrini et al.,
2009). Acylation of ghrelin occurs via activation of ghrelin-O-
acyl-transferase (GOAT) (Yang et al., 2008) whereas de-acylation
of ghrelin can be induced by the enzyme acyl-protein thioesterase
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1/lysophospholipase 1 (Satou et al., 2010; Stengel et al., 2011).
Diminished GHR signaling would be expected to occur after
inhibition of GHR or by activation of de-acylation of GHR.
Facilitation of GOAT function should enhance GHR signaling.
The ghrelin peptide is widely distributed throughout the gut
and the brain. Ghrelin is primarily secreted from the fundus of the
stomach and is transported into the brain across the blood brain
barrier (BBB) (Wren et al., 2001; Banks et al., 2002, 2008; Diano
et al., 2006). Ghrelin is expressed primarily within the arcuate
nucleus (ARC), the lateral hypothalamus (LH), the paraventric-
ular hypothalamic nucleus (PVN), portions of cortex, and the
dorsal vagal complex (Cowley et al., 2003; Cowley and Grove,
2004; Hou et al., 2006; Ferrini et al., 2009). Ghrelin receptors
appear to modulate a diverse set of physiological and behavioral
functions. Ghrelin receptors located within the pituitary (Kojima
et al., 1999) and the arcuate nucleus of the hypothalamus (Wren
et al., 2000; Mano-Otagiri et al., 2010) play a key role in the
release of growth hormone. In the hippocampus, ghrelin recep-
tors may promote long term potentiation (Diano et al., 2006;
Banks et al., 2008) and enhance memory consolidation (Carlini
et al., 2002; Hansson et al., 2011). Ghrelin receptors have been
localized on neurons within the ventral tegmental area (Guan
et al., 1997; Abizaid, 2009), which in turn project via themesolim-
bic dopamine (DA) pathway to multiple brain regions including
the nucleus accumbens (NACc), the amygdala, prefrontal cor-
tex and hippocampus (Fields et al., 2007). Modulation of the
mesolimbic dopamine system by ghrelin is likely involved in the
capacity of ghrelin to elicit eating and food-related reinforce-
ment (Dickson et al., 2011; Egecioglu et al., 2011; Skibicka and
Dickson, 2011) and also plays a key role in the behavioral activat-
ing and reward/reinforcement properties of drugs of abuse such
as cocaine and nicotine (Jerlhag et al., 2010; Dickson et al., 2011;
Wellman et al., 2011, 2012). Finally, ghrelin receptors located
on cells of the PVN may play a key role in activation of the
hypothalamic-pituitary-adrenal (HPA) axis (Asakawa et al., 2001;
Patterson et al., 2010; Cabral et al., 2012), which suggests a role
for ghrelin in stress.
Systemic ghrelin can rapidly exert changes in neuronal sig-
naling within the brain. Abizaid reported that systemic infu-
sion of GHR produced synaptic reorganization of neurons
within the VTA within 60min of exposure. VTA cells exposed
to ghrelin expressed more excitatory inputs and diminished
inhibitory inputs (Abizaid et al., 2006), an outcome similar to
that noted in the arcuate nucleus (Cowley et al., 2003; Cowley
and Grove, 2004), Systemic infusion of GHR can induce over-
flow of dopamine in the NACc on a time scale of minutes (Jerlhag
et al., 2006a,b; Quarta et al., 2009). These effects of ghrelin on
brain neuron function may occur through multiple pathways.
One pathway involves a potential activation of GHR-Rs located
on afferent fibers of the vagus (Date et al., 2002; Arnold et al.,
2006; De Lartigue et al., 2007; Date, 2012) that in turn project
to the brainstem. Another potential pathway involves permeation
of systemic GHR across the BBB (Banks et al., 2002, 2008; Diano
et al., 2006) in a bi-directional fashion (Banks et al., 2002). There
is evidence that nutritional state can modulate ghrelin transport
into brain with greater transport evident in fasted animals (Banks
et al., 2008).
PSYCHOSTIMULANTS AND GHRELIN
Psychostimulant drugs generally induce behavioral arousal, sup-
press eating, activate the reward system and, at high doses,
may induce symptoms of psychosis (Leibowitz, 1975; Wise and
Bozarth, 1987; Kalivas, 2000; Wellman et al., 2009). These effects
are often attributed to the capacity of these drugs to activate
dopamine-secreting neurons in brain, including neurons of the
mesolimbic and corticolimbic dopamine systems (Woolverton
and Kleven, 1988; Rothman and Baumann, 2003; Vezina, 2004;
Wise, 2004; Di Chiara and Bassareo, 2007). GHR-Rs are located
on neurons within the VTA (Guan et al., 1997; Naleid et al.,
2005; Abizaid et al., 2006; Diano et al., 2006; Zigman et al.,
2006; Abizaid, 2009). The VTA, in turn sends projections to
multiple regions including the NACc, amygdala, and prefrontal
cortex (Fields et al., 2007) and is thus positioned so as to mod-
ulate reinforcement to addictive drugs and natural reinforcers
that act via modulation of brain dopamine circuits (Jerlhag et al.,
2006a; Abizaid, 2009; Perello et al., 2010; Dickson et al., 2011).
In the subsequent sections, we consider strategies for induc-
tion of hyperghrelinemia and hypoghrelinemia in relation to
psychostimulant function.
STRATEGIES FOR MODULATION OF GHRELIN CIRCUITS
GHR acts as a neuromodulator at brain synapses—either increas-
ing or decreasing neuron activity. One strategy to assess GHR
function is to produce variation in plasma GHR levels. There are
endogenous rhythms of GHR secretion and these can be tem-
porally related to behavior and other motivated states. Feeding,
for example, is known to covary with the peaks and troughs of
GHR secretion (Cummings et al., 2001). A more common means
to induce hyperghrelinemia would involve exogenous administra-
tion of ghrelin or of drugs that act as GHR-R agonists. Systemic
or central injections of ghrelin or of GHR agonists are known
to induce eating as well as to activate brain mesolimbic circuits
involved in reinforcement (Abizaid et al., 2006; Jerlhag et al.,
2007; Jerlhag, 2008; Dickson et al., 2011; Skibicka and Dickson,
2011). However, a potential difficulty in such manipulations of
the GHR system is that GHR-Rs have a degree of constitutive
activity—that is, GHR-Rs may exhibit significant biological activ-
ity in the absence of ghrelin (Holst et al., 2003, 2004; Chollet
et al., 2009; Petersen et al., 2009) which may limit the magnitude
of changes induced by GHR administration or manipulation of
the GHR-R.
An alternative strategy to determine the importance of GHR
signaling for reinforcement involves inactivation of either GHR
or GHR-Rs. A variety of GHR inactivation strategies have been
developed (Allas and Abribat, 2013) including inhibition of the
enzyme (GOAT) that creates ghrelin (Yang et al., 2008; Al Massadi
et al., 2011; Davis et al., 2012; Allas and Abribat, 2013). One
recent study reported that knockout of GOAT function (Davis
et al., 2012), reduced ghrelin levels and resulted in diminished
intake of a palatable high-fat diet “dessert,” a measure of hedonic
eating. Other approaches include immunosuppression of ghre-
lin (Lu et al., 2009) and RNA silencing (Shrestha et al., 2009).
Spiegelmers are enantiomers of natural oligonucleotides that have
the capacity to bind a peptide such as ghrelin. Spiegelmers may
be resistant to degradation and thus may have a long duration
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of action (Kobelt et al., 2006). Ghrelin spiegelmers have been
used to block the orexigenic action of systemic ghrelin and to
block the induction by ghrelin of Fos within the arcuate nucleus
(Kobelt et al., 2006; Becskei et al., 2008). No study to date
has used this method to assess the role of ghrelin in reinforce-
ment. Genomic ablation of the protein that codes for ghrelin
has also been accomplished in mice (Sun et al., 2003, 2008)
which would allow for an assessment of ghrelin signaling in
reinforcement.
A key method for blocking the activation of GHR-Rs by ghre-
lin involves the use of drugs that function as GHR-R antagonists
(Asakawa et al., 2003; Halem et al., 2005; Salome et al., 2009a;
Jerlhag and Engel, 2011; Allas and Abribat, 2013; Moulin et al.,
2013). The impetus to develop pharmacological antagonists of
GHR-Rs is, in part, due to the linkage of GHR-R activation to the
induction of feeding (Nakazato et al., 2001; Depoortere, 2009),
with the hope that GHR-R inactivation might represent a ther-
apeutic approach for the treatment of obesity. One such drug is
the triazole derivative JMV 2959, a selective competitive GHR-
R antagonist (Moulin et al., 2007; Salome et al., 2009a,b). JMV
2959 binds to GHR-Rs with low nanomolar affinity (Salome et al.,
2009a). As would be expected of a GHR-R antagonist, systemic
administration of JMV 2959 dose-dependently blocked the feed-
ing response induced by the synthetic GHR agonist hexarelin
(Moulin et al., 2007). JMV 2959 thus represents an important
tool for the study of the role of GHR-Rs in drug abuse and other
functions.
Another GHR-R inactivation strategy involves genomic
manipulation (gene knockout), primarily in mice (Sun et al.,
2003, 2008). GHR-R null mice exhibit diminished behavioral
activation and reinforcement/reward in response to cocaine,
amphetamine and nicotine (Jerlhag et al., 2010; Abizaid et al.,
2011; Jerlhag and Engel, 2011; Wellman et al., 2011). GHR-R
ablation has also been accomplished in rats using N-ethyl-N-
nitrosourea (ENU)-driven target-selectedmutagenesis (Zan et al.,
2003; Till et al., 2007). GHR-R null rats do not overeat in response
to systemic injection (i.p.: 15 nmol) of GHR and importantly,
these rats exhibit diminished induction of locomotor sensitiza-
tion (relative to WT rats) when injected daily with 10mg/kg
cocaine HCl (Clifford et al., 2012). As discussed below, such rats
exhibit diminished reinforcement to low-level electrical stimula-
tion of the brain (Wellman et al., 2012).
In the subsequent sections, we consider a variety of issues relat-
ing to the interplay of ghrelin and of ghrelin receptors for the
impact of psychostimulant drugs such as cocaine, amphetamine
or nicotine on behavioral activation and reward/reinforcement.
GHRELIN MODULATES THE ACUTE HYPERLOCOMOTOR
EFFECTS OF COCAINE
To examine the potential role of ghrelin in psychostimulant
action, our preliminary studies focused on the impact of sys-
temic injections of ghrelin on cocaine hyper-locomotion and
cocaine-induced conditioned place preference (CPP). The sys-
temic injection route was chosen primarily because the gut is
the major source of body ghrelin. In our first study, we exam-
ined the impact of 5 nmol ghrelin on cocaine-induced hyper-
locomotion (Wellman et al., 2005). The 5 nmol ghrelin dose
was chosen, in part, because this dose induced a significant
interoceptive cue similar to that produced by food restriction
(FR) (Davidson et al., 2005) and secondly because this dose was
noted to induce Fos expression in the hypothalamus, but not
in the area postrema (Ruter et al., 2003). Male Sprague–Dawley
rats were pretreated at −60min with either 0 (vehicle) or 5 nmol
rat ghrelin (i.p.) and then injected (i.p.) at time 0 with 0, 2.5,
5.0, or 10.0mg/kg cocaine. Locomotor activity was monitored
over a 45-min post-cocaine period. Rats received the same ghre-
lin dose, but a different cocaine dose (in random order) on
each of the four drug trials, with each drug trial separated by at
least 2 days. Administration of 5 nmol ghrelin-0mg/kg cocaine
slightly increased locomotion relative to that of 0 nmol ghrelin-
0mg/kg cocaine. Cocaine increased locomotion as a function of
dose in the 0 nmol ghrelin group, but the effect of cocaine was
even greater when preceded by 5 nmol ghrelin. These results indi-
cate that acute injection of ghrelin, at a feeding-relevant dose,
augments the acute effects of cocaine on locomotion in rats. A
recent study by Jang and colleagues noted a similar outcomes
in that injections of ghrelin directly into the NACc enhanced
the hyperlocomotor effect of systemic cocaine (15mg/kg, i.p.),
whereas intra-NACc injections of a ghrelin receptor antagonist
prevented this effect (Jang et al., 2013). Although GHR-R mRNA
is sparse within the NACc, it is detectable and ghrelin infusions
into this region can elicit feeding (Naleid et al., 2005; Skibicka
et al., 2011a). These studies strongly suggest that acute ghrelin can
facilitate the hyperlocomotor effects of a psychostimulant such as
cocaine.
GHRELIN INDUCES CROSS-SENSITIZATION OF
HYPERLOCOMOTION TO COCAINE
The capacity for repeated administration of a psychostimulant
drug to produce behavioral sensitization (i.e., enhanced hyper-
locomotion) has been considered as a useful model for under-
standing the neural underpinnings of drug addiction (Wise and
Leeb, 1993; Miller et al., 1999; Davidson et al., 2002; Schoffelmeer
et al., 2002; Steketee and Kalivas, 2011). Given that ghrelin
alone can induce CPP (Bell et al., 1997) and that a single ghre-
lin injection can reorganize the inputs of the VTA (Abizaid
et al., 2006), we considered the possibility that elevated lev-
els of ghrelin could induce a form of central sensitization in
which such treated rats are more reactive to cocaine (Wellman
et al., 2008b). Male Sprague–Dawley rats were pretreated daily
for 7 days with 0, 5, or 10 nmol rat ghrelin (i.p.) in their
home cage. On the 8th day, rats were transported to a testing
room, placed in a locomotion chamber for 15min, and then
injected (i.p.) with either 0, 7.5, or 15mg/kg cocaine with loco-
motor activity monitored over a 45min post-cocaine period.
Pretreatment with 5 or 10 nmol ghrelin alone did not signifi-
cantly increase basal locomotion relative to that of the 0 nmol
ghrelin group. Rats pretreated with 5 or 10 nmol ghrelin showed
an enhanced locomotor response after treatment with 15mg/kg
cocaine relative to rats treated with 0 nmol ghrelin (Wellman
et al., 2008b). These results extend our acute locomotion data
and suggest that hyperghrelinemia can result in a form of
sensitization that facilitates the behavioral activating effects of
cocaine.
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GHRELIN ENHANCES COCAINE- AND FOOD-INDUCED CPP
CPP is a measure of the hedonic quality of a treatment in which
a treatment is paired repeatedly with a non-preferred spatial
location (Bardo and Bevins, 2000). After multiple pairings, sub-
jects are noted to spend more time in the initially non-preferred
location, an outcome which is taken as an indication of the
rewarding property of the treatment. Notably, systemic and cen-
tral administration of GHR alone can induce CPP (Jerlhag, 2008;
Jerlhag et al., 2010) and can enhance the CPP induced by cocaine
and by food (Davis et al., 2007; Egecioglu et al., 2010; Perello et al.,
2010). In a subsequent study, we determined that systemically
administered ghrelin (5 nmol/rat) can enhance the rewarding
properties of 0.3125 and 0.625mg/kg cocaine, as indexed by a
CPP procedure (Davis et al., 2007). The observation that sys-
temic ghrelin can facilitate the acquisition of CPP to low doses
of cocaine suggests that the facilitatory effect of increased ghre-
lin level is not limited to locomotion and suggests that the effect
is not one of a general non-specific enhancement of locomotion,
inasmuch as reward in the CPP paradigm is assessed long after the
ghrelin-drug pairing (Bardo and Bevins, 2000; Fields et al., 2007).
The capacity of ghrelin to facilitate reward is not limited to
psychostimulant-induced reward. Perello et al. (2010) reported
that the rewarding effect of exposure to a high-fat pellet in a
specific environment was enhanced by pretreatment with 2 ug/g
(∼18 nmol) ghrelin, but this effect was absent in mice pretreated
with a GHR-R antagonist. These latter results strongly implicate
ghrelin signaling in reward processes.
GHRELIN RECEPTOR ANTAGONISM ATTENUATES
PSYCHOSTIMULANT-INDUCED HYPERLOCOMOTION AND
REWARD
Our early experiments involving ghrelin and psychostimulants
focused on systemic administration of ghrelin, in part, because
of a lack of a readily available method of GHR-R antago-
nism. Subsequently, the ghrelin receptor antagonist JMV 2959,
was made available to our research group by Drs. Fehrentz
and Martinez (Salome et al., 2009a; Moulin et al., 2013).
Pharmacological inactivation of GHR-Rs by JMV 2959 has been
noted to attenuate or to ablate the acute hyperlocomotor and CPP
properties of amphetamine, cocaine, ethanol, and most recently
that of nicotine (Jerlhag et al., 2009, 2010, 2011; Jerlhag and
Engel, 2011). These findings indicate that ghrelin receptors exert
a permissive function for the activation of dopamine circuits by
psychostimulant drugs (and other drugs of abuse).
Of specific interest to us was the potential impact of GHR-R
antagonism on the development of sensitized hyper-locomotion
to psychostimulants such as cocaine or nicotine. As noted ear-
lier, repeated injections of ghrelin per se can produce a degree of
cross-sensitization to cocaine (Wellman et al., 2008b). Drug sen-
sitization reflects a form of neuronal plasticity in which repeated
drug administration leads to long-lasting increases in behavioral
activation and dopamine overflow within the NACc and it is
thought that these effects can lead to enhanced drug taking and
addiction (Robinson and Berridge, 2003; Vezina, 2004, 2007).
As such, manipulations that attenuate drug sensitization might
be of value for the conceptualization and perhaps treatment of
addiction either to block the acquisition of sensitization or to
block the expression of an already established drug sensitization.
Psychostimulants act via the mesolimbic pathway from the VTA
to NACc to induce behavioral activation and there is data to sug-
gest that the induction of behavioral induction of sensitization
most likely involves the VTA rather than the NACc (Cador et al.,
1995). Given an emerging literature linking GHR-Rs to the acti-
vation of the VTA (Guan et al., 1997; Cowley et al., 2003; Abizaid
et al., 2006; Zigman et al., 2006; Dickson et al., 2011; Skibicka
et al., 2011a), we sought to determine the impact of pharmacolog-
ical blockade of GHR-Rs using the GHR-R antagonist JMV 2959
(Moulin et al., 2007; Salome et al., 2009b) on the development of
locomotor sensitization induced by repeated exposure to nicotine
(Wellman et al., 2011) as well as to cocaine (Clifford et al., 2012).
In the nicotine study (Wellman et al., 2011), rats were treated
daily for 7 days with 0.4mg/kg nicotine (s.c), a dose sufficient to
result in behavioral sensitization. Half of the rats were pretreated
each day with either vehicle or 3mg/kg JMV 2959. Whereas rats
pretreated with vehicle and treated with nicotine developed a
robust hyperlocomotor sensitization (Figure 1A), pretreatment
with JMV 2959 abolished the development of nicotine sensitiza-
tion (Figure 1B). The impact of JMV on nicotine sensitization is
unlikely to be an artifact of the capacity of JMV 2959 to reduce
baseline locomotion. At this dose, there were no baseline dif-
ferences attributable to JMV 2959 (compare the vehicle-vehicle
group in Figure 1A with the JMV 3-vehicle group in Figure 1B).
In our cocaine study (Clifford et al., 2012), daily pretreatment
with JMV 2959 attenuated the development of locomotor sen-
sitization to 10mg/kg cocaine, but the magnitude of this effect
was less than that noted for nicotine. It should be noted that
Abizaid and colleagues have shown that genetic ablation of ghre-
lin diminished the development of locomotor sensitization of
cocaine-induced hyperlocomotion in mice (Abizaid et al., 2011),
an outcome which further supports our view that ghrelin and
ghrelin receptors may play a permissive role for the induction of
psychostimulant-induced locomotor sensitization.
FIGURE 1 | Mean group total changes in total distance traveled scores
(cm/45min). On day 0, the rats were injected with Veh at −5min prior to
the 15min baseline period and then again with Veh just prior to the 45min
test period. During days 1–7, the rats were injected with either Veh,
(panel A) or 3mg/kg JMV 2959 (JMV 3: panel B) at −5min prior to the
15min baseline period and then injected with either vehicle or 0.4mg/kg
nicotine (Nic) just prior to the 45min test period on days 1–7. The lines
above and below each symbol represent the SEM. Figure reprinted with
permission from Regulatory Peptides (Wellman et al., 2011). ∗p < 0.05.
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Although the aforementioned findings suggest a permissive
role for GHR-Rs for the induction of psychostimulant-induced
locomotor sensitization, no study to date has assessed whether
antagonism of GHR-Rs would diminish the expression of an
already established nicotine locomotor sensitization. In our JMV
2959-nicotine study, JMV 2959 was used throughout the course
of nicotine exposure (Wellman et al., 2011). What is needed is
an experiment in which nicotine sensitization is produced and
then animals are treated with either vehicle or JMV 2959. If
JMV 2959 has the capacity to block expression as well as induc-
tion of sensitization, this drug may be of value for the treatment
of smoking and perhaps other drugs of addiction (Kim et al.,
2011).
DOES GHRELIN CONTRIBUTE TO THE CAPACITY OF FOOD
RESTRICTION TO ENHANCE PSYCHOSTIMULANT ACTION?
FR can increase the rate of acquisition of learned responses for
many reinforcers, including food as well as the psychostimu-
lant drugs cocaine or amphetamine (Carroll and Meisch, 1981;
Carroll, 1985; Carr, 2002). A link between caloric homeosta-
sis and psychostimulant action in rats is further supported by
studies in which FR augments the capacity of psychostimulants
to enhance locomotion and to induce CPP (Bell et al., 1997;
Zheng et al., 2012). FR also augments the rewarding effects of
intracranial self-stimulation of the lateral hypothalamus (LH-
ICSS) (Cabeza De Vaca et al., 1998; Fulton et al., 2000); a model
system used to explore mechanisms that modulate reinforcement
function in brain (Olds and Milner, 1954; Wise, 1996). FR is
routinely used by addiction researchers employing intravenous
self-administration paradigms to enhance psychostimulant-based
reinforcement (Carroll et al., 1979; Carroll and Meisch, 1980,
1981; Carroll, 1985; Comer et al., 1995). Prior studies sug-
gested that signals related to the acute availability of metabolic
fuels (e.g., glucose, free fatty acids) are unlikely to wholly
account for FR-associated changes in psychostimulant action,
inasmuch as short-term glucoprivation or lipoprivation does
not alter LH-ICSS in FR rats (Cabeza De Vaca et al., 1998;
Fulton et al., 2000; Carr, 2002). Prolonged negative energy bal-
ance results in increased expression of neuropeptide Y (NPY)
in the hypothalamus; however, administration of NPY does not
alter LH-ICSS (Cabeza De Vaca et al., 1998). Thus, the mecha-
nism by which FR enhances psychostimulant effects has remained
elusive.
A variety of studies suggest that the orexigenic peptide ghrelin
may be the substrate through which FR acts to enhance psy-
chostimulant action. Human plasma ghrelin levels are at a nadir
after a meal and then peak prior to the next meal (Cummings
et al., 2001). Plasma ghrelin levels increase during periods of
FR, and decrease after eating (Toshinai et al., 2001). Importantly,
Davidson and colleagues (Davidson et al., 2005) noted that a
systemic infusion of ghrelin can generate an interoceptive food
cue that resembles that induced by food deprivation (for exam-
ple, 6 nmol GHR was noted to be comparable to the cue induced
by 24 h food deprivation). Collectively, these data suggested that
changes in peripheral ghrelin levels occasioned by FR could result
in changes in dopamine signaling in brain reinforcement sys-
tems that in turn may enhance psychostimulant action. Indeed,
our early studies which showed facilitation by ghrelin of acute
locomotion to cocaine (Wellman et al., 2005) and enhanced CPP
to cocaine (Davis et al., 2007) were generally consistent with
the notion that FR may act on a ghrelin-dependent substrate to
facilitate psychostimulant action.
To further examine the interaction of FR, ghrelin and psychos-
timulant function, we examined the capacity of FR to enhance
cocaine-induced hyper-locomotion in wild-type (WT) mice vs.
GHR-null or GHR-R null mice (Clifford et al., 2011). WT, GHR
null, and GHR-R null mice were either restricted to 60% of
baseline caloric intake (FR) or allowed to free-feed (FF). Mice
were treated with 0, 1.25, 2.5, and 5.0mg/kg cocaine on sepa-
rate test days (in random dose order) and forward locomotion
was recorded on each drug day for 45min after drug dosing. FR
increased locomotion scores in vehicle treatedWTmice, but these
increases were diminished in GHR-R and GHR null mice. The
doses of cocaine chosen in this study were low (0–5mg/kg) and
did not increase locomotion in FF mice, but produced similar
and significant increases in FR mice irrespective of ghrelin sta-
tus. These preliminary results did not support the contention that
GHR pathways are required for the capacity of FR to augment the
acute effect of cocaine on locomotion.
Zheng and colleagues conducted psychostimulant testing in
the ICSS paradigm during preprandial and postprandial periods
in rats fed a single meal per day that represented 40% of their
normal daily food intake (Zheng et al., 2013). In such a situation,
ghrelin levels are entrained to the feeding period such that ghre-
lin levels are high during the preprandial period, but low during
the postprandial period. Rats received vehicle or amphetamine
microinjections into the NACc shell region. All rats were food
restricted, but some were tested prior to a daily meal and oth-
ers tested after that meal. Amphetamine injections shifted the
ICSS rate-frequency curve to the left (an outcome indicating
enhanced reinforcement) but this effect did not vary by time of
feeding. These data suggest that endogenous variation of ghre-
lin levels of the magnitude noted under these testing conditions
was not sufficient tomodify psychostimulant reactivity in an ICSS
paradigm.
The relatively few studies that have examined the notion that
FR may act through a ghrelin-dependent substrate to modify
reinforcement are inconclusive. A firm conclusion as to whether
ghrelin plays a causal role in enhancing psychostimulant func-
tion requires additional study. A key issue is whether conditional
GHR-R knockouts would exert an effect on FR activation of psy-
chostimulant locomotion, as opposed to conventional knockouts
for which there may be compensations that develop over time.
Another issue is the relatively few methods employed to dimin-
ish GHR-R function. Additional studies should be conducted
using other methods of GHR-R antagonism such as pretreatment
with JMV 2959 or de-acylation of GOAT, as specific exam-
ples. Additional endpoints (other than locomotion) need to be
assessed including CCP as well as intravenous self-administration
of cocaine or nicotine. A final issue of concern is the fact that
GHR-Rs exhibit a degree of constitutive activity and thus may
modulate drug reinforcement, independent of FR and/or ghrelin
levels (Holst et al., 2003; Petersen et al., 2009; Steketee and Kalivas,
2011).
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STRESS, GHRELIN, AND FOOD RESTRICTION INTERACTIONS
WITH PSYCHOSTIMULANTS
Another issue regarding FR and enhancement of psychostimulant
function is that ghrelin and GHR-Rs may play an indirect role
via activation of the HPA axis. Stressors result in increased CRF
secretion from the PVN, secretion of ACTH and enhanced levels
of plasma glucocorticoids (GC) such as cortisol (Patterson et al.,
2010; Cabral et al., 2012). FR is well-known to enhance circulat-
ing levels of ghrelin (Stengel et al., 2011). Interestingly, various
forms of psychosocial stress can increase circulating ghrelin lev-
els in rodents (Asakawa et al., 2001; Patterson et al., 2010) as
well as humans (Rouach et al., 2007). Moreover, it appears that
ghrelin can activate the HPA axis, depending on dose and route
of administration. Doses of ghrelin that induce eating (30 nmol)
may not alter plasma corticosterone levels when given systemi-
cally (Wren et al., 2002). ICV infusion of ghrelin, however, elicits
increased plasma ACTH and corticosterone levels (Wren et al.,
2002; Stevanovic et al., 2007). Systemic ghrelin (∼18 nmol) indi-
rectly activates hypothalamic CRF neurons in mice (Cabral et al.,
2012). Another linkage between stress and GHR-R is that GHR-
R null mice show diminished HPA response to acute restraint
stress (Spencer et al., 2012). In a related vein, stress and enhanced
GC signaling has been found to facilitate psychostimulant func-
tion. Stress can enhance the magnitude of locomotor activation
induced by psychostimulant drugs (Piazza and Le Moal, 1996)
and can modify the acquisition (Campbell and Carroll, 2000),
maintenance (Carroll, 1985) and reinstatement (De Wit and
Stewart, 1981; Carroll, 1985) of self-administration patterns of
cocaine in rats (Goeders, 2002, 2003) as does FR (Carroll et al.,
1979; Carroll, 1985; Bell et al., 1997). In contrast, blockade of
corticosterone signaling can diminish the psychoactive effect of
cocaine (Piazza and Le Moal, 1996; Piazza et al., 1996; Marinelli
et al., 1997a,b).
These aforementioned studies raise the possibility that FR
may act indirectly by increasing GHR signaling which in turn
acts at the level of the hypothalamus to enhance the HPA axis
modulation of psychostimulant function, perhaps at the level of
the VTA (Piazza and Le Moal, 1996; Piazza et al., 1996; Goeders,
2002, 2003). Few studies, however, are available by which to eval-
uate this hypothesis. One negative finding is that generated by
Tessari et al. (2007) in which circulating corticosterone levels were
not positively related to the reinstatement of responding for intra-
venous cocaine in rats. In this same study, plasma levels of ghrelin
were related to reinstatement of responding for cocaine. Another
negative finding is that acute changes in corticosterone availabil-
ity does not alter the capacity of FR to sensitize LH-ICSS patterns
(Abrahamsen et al., 1995). The same laboratory, however, has
generated parallel data in which variation of ghrelin levels does
not alter ICSS patterns (Zheng et al., 2013).
Additional experiments are needed to evaluate the poten-
tial interaction of stress, GHR signaling and psychostimulant-
based reinforcement. A key issue is the need to examine the
impact of GHR-R antagonists on self-administration end-points
for cocaine and for nicotine. This would include studies of
maintenance levels of drug self-administration as well as rein-
statement of self-administration (Carroll, 1985; Goeders, 2002,
2003).
ROLE OF GHRELIN RECEPTORS IN ICSS AND DRUG
SELF-ADMINISTRATION
Although psychostimulant-induced locomotor sensitization is
thought to contribute to the development of addiction, loco-
motion is but a proxy for the processes that underlie rein-
forcement. A number of behavioral paradigms provide models
of reinforcement including intracranial self-stimulation (ICSS)
(Olds and Milner, 1954; Stein, 1964) and intravenous drug
self-administration (IVSA) (Brady and Griffiths, 1976; Carroll
and Meisch, 1981; De Wit and Stewart, 1981). In the fol-
lowing sections, we consider published studies in which ago-
nism/antagonism of GHR-Rs alters either ICSS rate-frequency
profiles or alters IVSA responding for cocaine and for heroin.
Ablation of the GHR-R in rats has been accomplished using
N-ethyl-N-nitrosourea (ENU)-driven target-selected mutagene-
sis (Zan et al., 2003; Till et al., 2007). GHR-R null rats do not
overeat in response to systemic injection (i.p.: 15 nmol) of GHR
and importantly, these rats exhibit diminished induction of loco-
motor sensitization (relative to WT rats) when injected daily with
10mg/kg cocaine (Clifford et al., 2011). A similar attenuation has
been noted in ghrelin null mice (Abizaid et al., 2011). Thus, the
lack of GHR or of GHR-Rs compromises the ability of a psychos-
timulant such as cocaine to induce hyperlocomotor sensitization.
To address the issue of whether GHR-null rats exhibit dimin-
ished brain reinforcement, we examined the reinforcing action of
ICSS in WT and GHR-R null rats. ICSS is a model of brain rein-
forcement in which animals can press a lever in order to deliver
a series of constant-current pulses via an electrode implanted
into brain reinforcement circuits (Wise, 1996; Kenny et al., 2003;
Carlezon and Chartoff, 2007; Wellman et al., 2008a). Adult male
WT and GHR-R null rats were implanted with a single electrode
aimed at the LH and then trained, after recovery, to lever-press
for ICSS (Wellman et al., 2012). In the rate-frequency procedure,
ICSS stimulation intensity is set at a minimum-to-moderate value
(75–120 uA) and responding is then recorded as stimulation fre-
quency is reduced in 0.05 log steps from 128Hz in each minute
over 15min (Carlezon and Chartoff, 2007; Zheng et al., 2013).
Responding usually decreases with lower stimulation frequencies.
In this study, WT littermates showed normal acquisition of ICSS
responding at an intensity of ∼70 uA. The lab technician run-
ning these rats during acquisition reported that the GHR-R null
rats failed to acquire until current intensity was raised 4-fold to
300 uA (see Figure 2 from Wellman et al., 2012). When current
intensity was dropped back to 75–100 uA, the GHR-R null did
not respond at any stimulation frequency. These results indicate
a permissive function for GHR-Rs in ICSS-based reinforcement
and generally support the proposition of ghrelin involvement in
central reinforcement.
There are multiple papers that demonstrate that GHR-R inac-
tivation attenuates the CPP induced by cocaine, amphetamine,
nicotine, and ethanol (Jerlhag et al., 2009, 2010, 2011; Dickson
et al., 2010; Jerlhag and Engel, 2011) as well as by food and by
novelty (Egecioglu et al., 2010; Hansson et al., 2012). Few stud-
ies, however, have more directly examined the role of GHR-Rs
in drug abuse using the IVSA method. In this procedure, rats are
trained to lever-press to deliver a drug bolus into their venous sys-
tem. One variation of the IVSAmethod involves assessment of the
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FIGURE 2 | Mean group Intracranial Self-Stimulation (ICSS)
rate-frequency scores for wild-type (WT: n = 5) and GHR-R null rats
(n = 6) as a function of stimulation intensity. WT rats tested at 75 uA
and GHR-R null rats tested at 300 uA exhibit overlapping rate-frequency
curves. When GHR-R null rats were tested at 75 uA, their rate-frequency
curves dropped to 0. Figure reprinted with permission from Addiction
Biology (Wellman et al., 2012).
impact of a particular pretreatment on responding for a particular
dose of a drug such as cocaine or nicotine (Carroll, 1985). Tessari
et al. (2007) reported that circulating GHR levels (but not plasma
levels of corticosterone) were positively related to the reinstate-
ment of responding for intravenous cocaine in rats. This study
indicates that augmenting GHR levels can facilitate the reinforc-
ing actions of cocaine. An implication of this study is that high
plasma ghrelin levels may predispose to relapse in persons for-
merly addicted to cocaine. A similar effect was noted in a report
from Shalev’s group in which intracerebroventricular infusions
of ghrelin (0.0, 1.5, and 3.0 ug/rat) produced increases in break-
points on a progressive ratio schedule of heroin reinforcement
(Maric et al., 2011).
Another variation of the IVSA method is to examine the
potential impact of GHR-R antagonist on reinstatement of previ-
ously extinguished drug responding (De Wit and Stewart, 1981;
Carroll, 1985). To date, no published study has considered the
impact of pretreatment with a GHR-R antagonist onmaintenance
patterns of responding for cocaine, nicotine or other psychos-
timulants. With regard to opiate drug self-administration, central
administration of the ghrelin receptor antagonist, [D-Lys-3]-
GHRP-6 (0.0 or 20.0 ug/rat) had no effect on ongoing heroin
self-administration and did not alter reinstatement of heroin
responding. To date, this latter work is the only published report
to examine the interaction of ghrelin systems and opiate rein-
forcement. Additional studies of IVSA for cocaine, amphetamine,
nicotine and heroin are in order using GHR agonists as well as
multiple GHR-R antagonist methods.
CONCLUSIONS
The current literature strongly supports a key role for GHR-Rs
within the VTA for the induction of reinforcement for multiple
classes of reinforcers including food and perhaps other natural
rewards, drugs of abuse and novelty (Jerlhag et al., 2009, 2010;
Perello et al., 2010; Dickson et al., 2011; Egecioglu et al., 2011;
Jerlhag and Engel, 2011; Skibicka and Dickson, 2011; Hansson
et al., 2012; Wellman et al., 2012). The prominent role of GHR-
Rs in reinforcement suggests that therapeutic interventions that
target these receptors may be of value. Of particular interest for
our laboratory is the extent to which GHR-R modulation may
offer a valuable route for the treatment of smoking addiction.
This disorder remains intractable with few effective therapies
available (Laniado-Laborin, 2010). Acute nicotine induces hyper-
locomotion, CPP and overflow of DA within the NACc (Jerlhag
and Engel, 2011). GHR-Rs are located on cholinergic afferents
arising from the laterodorsal tegmental area (LDTg) that project
to the VTA, which in turn activate dopamine overflow within
the NACc (Jerlhag et al., 2006a). Intra-LDTg infusion of ghre-
lin enhances locomotion and induces NACc dopamine release
(Jerlhag et al., 2007). Within the VTA, GHR-Rs and choliner-
gic receptors are located on DA neurons that project to the
VTA (Dickson et al., 2011: cf. Figure 1, page 82)—thus nico-
tine may directly alter activity of VTA neurons. In contrast, acute
pharmacological blockade of GHR-Rs blocks nicotine-induced
locomotion, the induction of CPP by nicotine, and dopamine
overflow within the NAcc (Jerlhag and Engel, 2011). Our pre-
liminary behavioral studies (Wellman et al., 2011, 2012) indi-
cate that a drug such as JMV 2959 may offer a route to block
nicotine-induced reinforcement, which would be of value for
smoking cessation. Additional studies are required to confirm
these observations and to demonstrate that GHR-R antagonists
can promote smoking abstinence. It is likely that modulation
of GHR-Rs may be of use for other drugs of abuse, such as
cocaine, alcohol and heroin (Jerlhag et al., 2009, 2010;Maric et al.,
2011).
It seems likely that ghrelin acts via multiple circuits to elicit
eating (Cowley and Grove, 2004; Naleid et al., 2005; Dickson
et al., 2011). A dense concentration of ghrelin receptor pro-
tein is localized within the arcuate hypothalamus (Harrold et al.,
2008). Ghrelin infusion into the ARC can trigger the release of
feeding-relevant peptides and neurotransmitters, which in turn
influence food intake and play a role in controlling energy home-
ostasis (Bagnasco et al., 2003; Cowley et al., 2003; Sato et al.,
2005). Ghrelin can alter arcuate nucleus inputs by augmenting
NPY signaling, which stimulates food intake, and diminishing
proopiomelanocortin (POMC) signaling, which plays a role in
the induction of satiety (Cowley et al., 2003). Ghrelin neurons
project from the hypothalamus to the brainstem—these fibers
likely interact with the cells of the dorsal vagal complex that can
also modulate eating (Hou et al., 2006; Hori et al., 2008). In addi-
tion to the arcuate nucleus, acute and chronic injections of ghrelin
into the VTA as well as the NACc can induce eating (Naleid et al.,
2005; King et al., 2011; Skibicka andDickson, 2011; Skibicka et al.,
2011a). Additionally, VTA neurons receive inputs from orexin
neurons in the LH, which are also sensitive to ghrelin. What is
unknown at the present time is whether these are truly indepen-
dent circuits or whether these reflect interconnections between
these circuits (i.e., involving arcuate or lateral hypothalamic to
VTA projections) or interconnections between the NACc and
the hypothalamus (Kelley et al., 2005; Dickson et al., 2011). The
rewarding effects of palatable food consumption appears to be
ghrelin-dependent for both sweets and fats (Egecioglu et al., 2010;
Perello et al., 2010; Skibicka and Dickson, 2011; Skibicka et al.,
2011b). The involvement of ghrelin for palatable food reward is
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fascinating since this suggests that antagonism of GHR-Rs may
be of value in helping persons to control their overconsumption
of palatable foods, which would be of assistance for the treat-
ment of being overweight. Another therapeutic issue for the use
of GHR-R antagonists follows from the observation that persons
smoke for multiple reasons. Some persons smoke because they
enjoy the reinforcement elicited by nicotine but another factor is
that smoking can allow people to overeat fat, calories and alco-
hol (Dallongeville et al., 1998) all while weighing less than normal
(Klesges et al., 1989; Zoli and Picciotto, 2012). Cessation of smok-
ing can result in weight gain which can be viewed as unacceptable
and therefore diminish treatment compliance (Pomerleau and
Saules, 2007). To date, we have few effective interventions by
which to limit smoking cessation weight gain (Farley et al., 2012).
GHR-R drug antagonists may therefore have a dual utility for the
treatment of nicotine addiction: the first being antagonism of the
rewarding action of nicotine; the second being obviation of the
weight gain often noted following smoking cessation.
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